title: Recent advances in T-cell immunotherapy for haematological malignancies.
abstract: In vitro discoveries have paved the way for bench-to-bedside translation in adoptive T cell immunotherapy, resulting in remarkable clinical responses in a variety of haematological malignancies. Adoptively transferred T cells genetically modified to express CD19 CARs have shown great promise, although many unanswered questions regarding how to optimize T-cell therapies for both safety and efficacy remain. Similarly, T cells that recognize viral or tumour antigens though their native receptors have produced encouraging clinical responses. Honing manufacturing processes will increase the availability of T-cell products, while combining T-cell therapies has the ability to increase complete response rates. Lastly, innovative mechanisms to control these therapies may improve safety profiles while genome editing offers the prospect of modulating T-cell function. This review will focus on recent advances in T-cell immunotherapy, highlighting both clinical and pre-clinical advances, as well as exploring what the future holds.
authors.affiliation: Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital, Houston, TX, USA.|Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, TX, USA.
authors.forename: Rayne H
authors.initials: RH
authors.lastname: Rouce
authors.affiliation: Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital, Houston, TX, USA.
authors.forename: Sandhya
authors.initials: S
authors.lastname: Sharma
authors.affiliation: Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital, Houston, TX, USA.
authors.forename: Mai
authors.initials: M
authors.lastname: Huynh
authors.affiliation: Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital, Houston, TX, USA.
authors.forename: Helen E
authors.initials: HE
authors.lastname: Heslop
mesh_terms: D018941:Antigens, CD19 / Q000276:immunology; D019337:Hematologic Neoplasms / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods* / Q000639:trends; D016219:Immunotherapy, Adoptive / Q000379:methods / Q000639:trends; D013601:T-Lymphocytes / Q000276:immunology / Q000637:transplantation
chemical_list: D018941:Antigens, CD19
keywords: T cells; immunotherapy; lymphoma